Aim: To study the effect of pentoxifylline in glaucomatous optic atrophy. Materials And Methods: The present prospective interventional comparative study was conducted among patients attending the out-patient department of Ophthalmology of Lala Lajpat Rai and associated Hospitals, Kanpur were selected. Patients were divided into 2 groups according to best corrected visual acuity (BCVA)-, first group having BCVA ≤20/200(6/60) and second having BCVA >20/200(6/60). In each group further division was made into cases control randomly. 49 eyes (39 patients) were taken in cases and 40 eyes (22 patients) were taken in control group. 33 and 16 eyes were selected for cases having BCVA >20/200 and ≤20/200 respectively. 26 and 14 eyes were selected for control having BCVA >20/200 and ≤20/200 respectively. They underwent detailed history and clinical examination. Patients with primary glaucoma – open angle, closed angle, and normal tension glaucoma were selected. Best corrected visual acuity with logmar chart, IOP with applanation tonometer, baseline IOP, IOP on follow-ups, Fundus examination (ophthalmoscopy), detailed slit lamp examination, visual fields by Humphrey field analyzer, Pachymetry (A scan) and Gonioscopy by Goldmann 3 mirror contact lens was recorded. Results: Mean improvement of BCVA in first group was 0.02 (SD±0.01) and second group was 0.043 (SD±0.01) in cases (statistically insignificant) at the end of 6 month. In controls, first group had no change in BCVA whereas in second group there was mean deterioration of 0.002 (SD±0.00) (statistically insignificant) at the end of 6 month. Pentoxifylline does not have any significant effect on intraocular pressure. Conclusion: Patients of glaucomatous optic atrophy on pentoxifylline did not have statistically significant improvement in their BCVA. Pentoxifylline does not have any significant effect on intraocular pressure, fundus picture and visual fields during 6 month of therapy.